Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders …

Behavioral SymptomsSuicideSelf-Injurious Behavior+18 more

~Estimated

~$10 – $675

National Institute of Mental Health (NIMH)NCT06462196

Phase 2

An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, …

SuicideDepressive Disorder, Treatment-ResistantKetamine+10 more

~Estimated

~$10 – $5,625

National Institute of Mental Health (NIMH)NCT06511908

Phase 3

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if n…

Severe DepressionModerate DepressionKetamine+14 more

~Estimated

~$10 – $7,500

Theresa Jacob, PhD, MPHNCT06752759